Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection;A krónikus hepatitis C-vírus-fertozés hagyományos pegilált interferon+ribavirin és proteázgátló direkt antivirális hatású szerekkel kiegészített kezelésének mellékhatásai

Orvosi Hetilap

Volumn 152, Issue 50, 2011, Pages 1997-2009

  Hunyady, Béla ^a,b   Kovács, Balázs ^a   Battyáni, Zita ^a  

^a Belgyógyászati Osztály ^*  (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

adverse drug reaction; boceprevir; direct acting antiviral agents; hepatitis C virus; pegylated interferon; ribavirin; telaprevir; viral hepatitis

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; DYSGEUSIA; GENOTYPE; GOLD STANDARD; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MORTALITY; PHYSICIAN; PREVALENCE; RASH; TREATMENT RESPONSE;

AFFECT; ANEMIA, HYPOCHROMIC; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCRINE SYSTEM DISEASES; EYE; HEPATITIS C, CHRONIC; HUMANS; INFECTION; INTERFERON-ALPHA; NEUTROPENIA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RESPIRATORY SYSTEM; RIBAVIRIN; RISK FACTORS; THROMBOCYTOPENIA;

EID: 82455186322     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29266     Document Type: Article

References (68)

1. Cornberg, M., Razavi, H. A., Alberti, A. és mtsai: A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int., 2011, 31 (Suppl. 2), 30-60
2. Deuffic, S., Poynard, T., Valleron, A. J.: Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J. Viral Hepat., 1999, 6, 411-413. (Pubitemid 29470172)
3. Fried, M. W., Shiffman, M. L., Reddy, K. R. és mtsai: Peginter-feron alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347, 975-982.
4. Hadziyannis, S. J., Sette, H. Jr., Morgan, T. R. és mtsai: Peginter-feron-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and riba-virin dose. Ann. Intern. Med., 2004, 140, 346-355.
5. Manns, M. P., McHutchison, J. G., Gordon, S. C. és mtsai: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358, 958-965. (Pubitemid 32913521)
6. McHutchison, J. G., Lawitz, E. J., Shiffman, M. L. és mtsai: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, 361, 580-593.
7. Kwo, P. Y., Lawitz, E. J., McCone, J. és mtsai: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 2010, 376, 705-716. (SPRINT-1 vizsgálat)
8. Poordad, F., McCone, J. Jr., Bacon, B. R. és mtsai: Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1195-1206. (SPRINT-2 vizsgálat)
9. Bacon, B. R., Gordon, S. C., Lawitz, E. és mtsai: Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1207-1217. (RESPOND-2 vizsgálat)
10. McHutchison, J. G., Everson, G. T., Gordon, S. C. és mtsai: Tel-aprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med., 2009, 360, 1827-1838. (PROVE1 vizsgálat)
11. Hezode, C., Forestier, N., Dusheiko, G. M. és mtsai: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360, 1839-1850. (PROVE2 vizs-gálat)
12. McHutchison, J. G., Manns, M. P., Muir, A. J. és mtsai: Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med., 2010, 362, 1292-1303. (PROVE3 vizsgálat)
13. Jacobson, I. M., McHutchison, J. G., Dusheiko, G. M., és mtsai: Tel-aprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med., 2011, 364, 2405-2416. (ADVANCE vizsgálat)
14. Zeuzem, S., Andreone, P., Pol, S. és mtsai: Telaprevir for retreat-ment of HCV infection. N. Engl. J. Med., 2011, 364, 2417-2428. (REALIZE vizsgálat)
15. Gervais, A., Boyer, N., Marcellin, P.: Tolerability of treatments for viral hepatitis. Drug Safety, 2001, 24, 375-384. (Pubitemid 32417536)
16. McHutchison, J. G., Manns, M. P., Patel, K. és mtsai: Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology, 2002, 123, 1061-1069.
17. Sulkowski, M. S., Cooper, C., Hunyady, B. és mtsai: Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat. Rev. Gastroenterol. Hepatol., 2011, 8, 212-223.
18. Sulkowski, M. S., Wasserman, R., Brooks, L. és mtsai: Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J. Viral. Hepat., 2004, 11, 243-250. (Pubitemid 38658449)
19. Reddy, K. R., Shiffman, M. L., Morgan, T. R. és mtsai: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin. Gastroenterol. Hepatol., 2007, 5, 124-129. (Pubitemid 46096836)
20. Fellay, J., Thompson, A. J., Ge, D. és mtsai: ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature, 2010, 464, 405-408.
21. Schmid, M., Kreil, A., Jessner, W. és mtsai: Suppression of haema-topoiesis during therapy of chronic hepatitis C with different in-terferon alpha mono and combination therapy regimens. Gut, 2005, 54, 1014-1020. (Pubitemid 40873919)
22. Aslam, A. K., Singh, T.: Aplastic anemia associated with inter-feron beta-1a. Am. J. Ther., 2002, 9, 522-523.
23. Sulkowski, M. S., Poordad, F., Manns, M. P. és mtsai: Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J. Hepatol., 2011, 54 (Suppl. 1), S194-S195. (EASL 2011, abstract 476)
24. Sulkowski, M. S., Reddy, R., Afdhal, N. H. és mtsai: Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLU-MINATE phase 3 studies. J. Hepatol. 2011, 54 (Suppl. 1), S195. (EASL 2011, abstract 477)
25. Afdhal, N. H., Dieterich, D. T., Pockros, P. J. és mtsai: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology, 2004, 126, 1302-1311. (Pubitemid 38552795)
26. Falasca, K., Ucciferri, C., Mancino, P. és mtsai: Use of epoetin beta during combination therapy of infection with hepatitis C virus with ribavirin improves a sustained viral response. J. Med. Virol., 2010, 82, 49-56.
27. Shiffman, M. L., Salvatore, J., Hubbard, S. és mtsai: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavi-rin, and epoetin alpha. Hepatology, 2007, 46, 371-379. (Pubitemid 47344771)
28. Shiffman, M. L., Long, A. G.: Strategies to maintain quality of life and minimize adverse events in patients receiving hepatitis C therapy. www.clinicaloptions.com/battling
29. Antonini, M. G., Babudieri, S., Maida, I., és mtsai: Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection, 2008, 36, 250-255.
30. Yang, J. F., Hsieh, M. Y., Hou, N. J. és mtsai: Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment. Pharmacol. Ther., 2009, 29, 1000-1010.
31. Roomer, R., Hansen, B. E., Janssen, H. L. és mtsa: Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2010, 52, 1225-1231.
32. Roomer, R., Hansen, B. E., Janssen, H. L. és mtsa: Thrombocyto-penia and the risk of bleeding during treatment with peginter-feron alfa and ribavirin for chronic hepatitis C. J. Hepatol., 2010, 53, 455-459.
33. Constant, A., Castera, L., Dantzer, R. és mtsai: Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry, 2005, 66, 1050-1057. (Pubitemid 41191799)
34. Raison, C. L., Demetrashvili, M., Capuron, L. és mtsa: Neuropsy-chiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs, 2005, 19, 105-123. (Pubitemid 40321763)
35. Shaefer, M.: Management of side effects of interferon alfa and ribavirin-based treatment of chronic hepatitis C: Psychiatric side effects. Hot Topics In Viral Hepatitis, 2008, 9, 11-20.
36. Schaefer, M., Hinzpeter, A., Mohmand, A. és mtsai: Hepatitis C treatment in "difficult to treat" psychiatric patients with pegylat-ed interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology, 2007, 46, 991-998. (Pubitemid 350144763)
37. Mistler, L. A., Brunette, M. F., Marsh, B. J. és mtsai: Hepatitis C treatment for people with severe mental illness. Psychosomatics, 2006, 47, 93-107. (Pubitemid 43346956)
38. Nickel, T., Sonntag, A., Backmund, M. és mtsa: Depression during therapy with interferon alpha-how long should an antide-pressant treatment last? Pharmacopsychiatry, 2005, 38, 102-104. (Pubitemid 40388793)
39. Dove, L. M., Rosen, R. C., Ramcharran, D. és mtsai: Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 2009, 137, 873-884.
40. Manns, M. P., Rambusch, E. G.: Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J. Hepatol., 1999, 31 (Suppl. 1), 39-42. (Pubitemid 30002689)
41. Tran, H. A., Jones, T. L., Batey, R. G.: The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination interferon-alpha2beta and ribavirin. BMC Endocr. Disord., 2005, 5, 8.
42. Tomer, Y., Blackard, J. T., Akeno, N.: Interferon alpha treatment and thyroid dysfunction. Endocrinol. Metab. Clin. North Am., 2007, 36, 1051-1066. (Pubitemid 350026253)
43. Prummel, M. F., Laurberg, P.: Interferon-alpha and autoimmune thyroid disease. Thyroid, 2003, 13, 547-551.
44. Schreuder, T. C., Gelderblom, H. C., Weegink, C. J. és mtsai: High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int., 2008, 28, 39-46.
45. Fabris, P., Floreani, A., Tositti, G. és mtsai: Type 1 diabetes mel-litus in patients with chronic hepatitis C before and after inter-feron therapy. Aliment. Pharmacol. Ther., 2003, 18, 549-558. (Pubitemid 37186604)
46. Niewold, T. B., Swedler, W. I.: Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vascu-litis associated with hepatitis C. Clin. Rheumatol., 2005, 24, 178-181. (Pubitemid 40552976)
47. Olivieri, I., Palazzi, C., Padula, A.: Hepatitis C virus and arthritis. Rheum. Dis. Clin. North Am., 2003, 29, 111-122. (Pubitemid 36298106)
48. Wilson, L. E., Widman, D., Dikman, S. H. és mtsa: Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum., 2002, 32, 163-173. (Pubitemid 36043715)
49. Saadoun, D., Resche-Rigon, M., Thibault, V. és mtsai: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum., 2006, 54, 3696-3706. (Pubitemid 44737183)
50. Gallelli, L., Ferraro, M., Mauro, G. F. és mtsa: Generalised dermatitis induced by pegylated interferion alpha 2b in a patient infected with genotype-1 hepatitis C virus-presentation of a case. Clin. Drug Investig., 2005, 25, 281-284. (Pubitemid 40593617)
51. Grossmann, S. D. C., Teixeira, R., de Aguiar, M. C. F. és mtsa: Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Eur. J. Gastroenterol. Hepatol., 2008, 20, 702-706.
52. Hashimoto, Y., Kanto, H., Itoh, M.: Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J. Dermatol., 2007, 34, 577-582. (Pubitemid 47228537)
53. Kartal, E. D., Alpat, S. N., Ozgunes, I. és mtsa: Reversible alopecia universalis secondary to PEG-interferon alpha-2b and riba-virin combination therapy in a patient with chronic hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol., 2007, 19, 817-820. (Pubitemid 47266714)
54. Yurci, A., Guven, K., Torun, E. és mtsai: Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur. J. Gas-troenterol. Hepatol., 2007, 19, 811-815. (Pubitemid 47266713)
55. Veldt, B. J., Schalm, S. W., Janssen, H. L. A.: Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. J. Clin. Gastroenterol., 2007, 41, 432. (Pubitemid 46573076)
56. Cappell, M. S.: Colonic toxicity of administered drugs and chemicals. Am. J. Gastroenterol., 2004, 99, 1175-1190. (Pubitemid 38917825)
57. Leung, Y., Urbanski, S. J., Schindel, L. és mtsa: Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can. J. Gastroenterol., 2006, 20, 661-663. (Pubitemid 44781905)
58. Scherzer, T. M., Staufer, K., Novacek, G. és mtsai: Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment. Pharmacol. Ther., 2008, 28, 742-748.
59. Kumar, K. S., Russo, M. W., Borczuk, A. C. és mtsai: Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am. J. Gastroenterol., 2002, 97, 2432-2440.
60. Kanazawa, H., Yoshikawa, J.: Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. Am. J. Med., 2004, 116, 749-752. (Pubitemid 38622311)
61. Hurst, E. A., Mauro, T.: Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch. Dermatol., 2005, 141, 865-868. (Pubitemid 41058068)
62. Slavenburg, S., Heijdra, Y. F., Drenth, J. P.: Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig. Dis. Sci., 2010, 55, 579-585.
63. Dhillon, S., Kaker, A., Dosanjh, A. és mtsai: Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig. Dis. Sci., 2010, 55, 1785-1790.
64. Macedo, G., Ribeiro, T.: Interferon plus ribavirin: a cautionary note. Am. J. Gastroenterol., 1999, 94, 3087-3088. (Pubitemid 29482803)
65. Condat, B., Asselah, T., Zanditenas, D. és mtsai: Fatal cardiomyo-pathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. Eur. J. Gastroenterol. Hepatol., 2006, 18, 287-289.
66. Boonen, A., Stockbrugger, R. W., van der Linden, S.: Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin. Rheumatol., 1999, 18, 177-179. (Pubitemid 29223045)
67. Narkewicz, M. R., Rosenthal, P., Schwarz, K. B. és mtsai: Oph-thalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J. Pediatr. Gastroenterol. Nutr., 2010, 51, 183-186.
68. Lim, J. W., Shin, M. C.: Pegylated interferon associated retinopa-thy in chronic hepatitis patients. Ophthalmologica, 2010, 224, 224-229.